Lomecel-B Injection for Hypoplastic Left Heart Syndrome
(ELPIS II Trial)
Trial Summary
What is the purpose of this trial?
The purpose of this study is to test whether Lomecel-B™ works in treating patients with hypoplastic left heart syndrome (HLHS) and to gather additional information about the safety of Lomecel-B. Lomecel-B contains human mesenchymal stem cells (MSCs) as the active ingredient. MSCs are special cells in the body that are able to change into other types of cells, such as heart, blood, and muscle cells. MSCs are found in various tissues of the body, such as the bone marrow, which is the spongy tissue inside of your bones. Lomecel-B uses MSCs from bone marrow of unrelated young healthy donors. These are called "allogeneic", and do not require donor matching to the patient.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
What data supports the effectiveness of the treatment Lomecel-B Injection for Hypoplastic Left Heart Syndrome?
Research suggests that mesenchymal stem cells, like those in Lomecel-B, may help improve heart function in conditions similar to hypoplastic left heart syndrome by supporting the heart's ability to pump blood. Studies in animals and early human trials have shown potential benefits in heart function, which is promising for future treatment options.12345
Is Lomecel-B Injection safe for humans?
How is the Lomecel-B treatment different from other treatments for hypoplastic left heart syndrome?
Lomecel-B is unique because it uses mesenchymal stem cells (special cells that can develop into different types of cells) to potentially improve heart function in children with hypoplastic left heart syndrome, aiming to enhance the right ventricle's performance and possibly delay or avoid heart transplantation, unlike traditional surgical methods.145910
Research Team
Stu Berger, MD
Principal Investigator
Ann & Robert H Lurie Children's Hospital of Chicago
Eligibility Criteria
This trial is for patients with Hypoplastic Left Heart Syndrome (HLHS) who are scheduled for Stage II heart surgery. It's not suitable for those unwilling to follow the study plan, with pacemakers, needing additional heart surgeries at the time of Stage II operation, or infected with HIV/HBV/HCV. People allergic to DMSO can't join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Lomecel-B injections during their Stage II palliation
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Lomecel-B
Lomecel-B is already approved in United States for the following indications:
- None approved; under investigation for Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s Disease, and Aging-related Frailty
Find a Clinic Near You
Who Is Running the Clinical Trial?
Longeveron Inc.
Lead Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
The University of Texas Health Science Center, Houston
Collaborator